Adoptive transfer of tumor-specific Th9 cells eradicates heterogeneous antigen-expressing tumor cells

Kevin Sek; Cheok Weng Chan; Paul A Beavis; Phillip K Darcy

doi:10.1016/j.ccell.2021.10.013

Adoptive transfer of tumor-specific Th9 cells eradicates heterogeneous antigen-expressing tumor cells

Cancer Cell. 2021 Dec 13;39(12):1564-1566. doi: 10.1016/j.ccell.2021.10.013. Epub 2021 Nov 4.

Authors

Kevin Sek¹, Cheok Weng Chan¹, Paul A Beavis², Phillip K Darcy³

Affiliations

¹ Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne 3000, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville 3010, Australia.
² Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne 3000, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville 3010, Australia. Electronic address: paul.beavis@petermac.org.
³ Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne 3000, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville 3010, Australia; Department of Pathology, University of Melbourne, Parkville 3010, Australia; Department of Immunology, Monash University, Clayton, Australia. Electronic address: phil.darcy@petermac.org.

PMID: 34739846
DOI: 10.1016/j.ccell.2021.10.013

Abstract

In this issue of Cancer Cell, Xue et al. demonstrate that adoptive transfer of tumor-specific Th9 cells can eradicate established tumors containing antigen-loss-variant cells (ALVs) through both direct killing and bystander effects mediated by intratumoral accumulation of extracellular ATP (eATP) that promotes monocyte infiltration and stimulation of IFNα/β production.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adoptive Transfer
Humans
Neoplasms* / genetics
Neoplasms* / therapy